Showing results (81-90 of 114) with videos related to
Sort By:
Pageof 12
BMC Cancer|November 25, 2010
Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancerElton Rexhepaj, Karin Jirstrom, Darran P O'Connor, et al.Clinical Chemistry|April 18, 2015
Validation of new cancer biomarkers: a position statement from the European group on tumor markersMichael J Duffy, Catharine M Sturgeon, György Sölétormos, et al.Investigational New Drugs|October 14, 2020
The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cellsDalal AlSultan, Emma Kavanagh, Shane O'Grady, et al.Glycobiology|June 29, 2010
Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patientsAisling Pierce, Radka Saldova, Umi M Abd Hamid, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 12, 2005
Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodesLouise M Kelly, Yvonne Buggy, Arnold Hill, et al.Journal of Proteome Research|December 17, 2009
Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verificationThomas Y K Lau, Karen A Power, Sophie Dijon, et al.Breast Cancer Research : BCR|October 25, 2008
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancerElton Rexhepaj, Donal J Brennan, Peter Holloway, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistanceDonal J Brennan, Karin Jirstrom, Asa Kronblad, et al.Molecular Cancer Therapeutics|May 27, 2010
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinibNeil A O'Brien, Brigid C Browne, Lucy Chow, et al.Cancer Research|March 3, 2006
Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patientsAlexei Y Savinov, Albert G Remacle, Vladislav S Golubkov, et al.Pageof 12